Otsuka says Phase 3b study shows SIMTRIYO improves ADHD and anxiety scores in adults with comorbid anxiety disorders
Otsuka presented new Phase 3b analyses at Psych Congress 2026 on SIMTRIYO (centanafadine) in adults with ADHD plus anxiety disorders. Expanded results built on topline findings released in June, showing consistent symptom improvement across clinician-rated and patient-reported measures. Data also pointed to gains in day-to-day executive functioning and emotional regulation, supporting use in a clinically complex adult population. Safety profile broadly matched prior centanafadine studies, with gastrointestinal effects and reduced appetite among the most common side effects. Update follows FDA clearance of SIMTRIYO for ADHD in patients aged 6 and older, with DEA scheduling still under review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otsuka Holdings Co. Ltd. published the original content used to generate this news brief via (Ref. ID: 202609182015BIZWIRE_USPR_____20260918_BW619838) on September 19, 2026, and is solely re
Otsuka presented new Phase 3b analyses at Psych Congress 2026 on SIMTRIYO (centanafadine) in adults with ADHD plus anxiety disorders. Expanded results built on topline findings released in June, showing consistent symptom improvement across clinician-rated and patient-reported measures. Data also pointed to gains in day-to-day executive functioning and emotional regulation, supporting use in a clinically complex adult population. Safety profile broadly matched prior centanafadine studies, with gastrointestinal effects and reduced appetite among the most common side effects.
Update follows FDA clearance of SIMTRIYO for ADHD in patients aged 6 and older, with DEA scheduling still under review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otsuka Holdings Co.
Ltd. published the original content used to generate this news brief via (Ref. ID: 202609182015BIZWIRE_USPR_____20260918_BW619838) on September 19, 2026, and is solely responsible for the information contained therein. (C)